Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
3.300
-0.020 (-0.60%)
At close: Aug 13, 2025, 4:00 PM
3.300
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:35 AM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,125,597
Profits / Employee
-$201,569
Market Cap
874.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AKBA News
- 6 days ago - Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 8 days ago - Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference - GlobeNewsWire
- 10 days ago - Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - GlobeNewsWire
- 12 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewsWire
- 6 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire